<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432286</url>
  </required_header>
  <id_info>
    <org_study_id>16352</org_study_id>
    <secondary_id>I5Q-MC-CGAS</secondary_id>
    <secondary_id>2017-004351-23</secondary_id>
    <nct_id>NCT03432286</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</brief_title>
  <acronym>REBUILD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety and efficacy of the study drug
      galcanezumab in participants 6 to 17 years of age with episodic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">July 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 4, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headache days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days</measure>
    <time_frame>3 Months</time_frame>
    <description>Proportion of participants with reduction from baseline ≥50% in monthly migraine headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days with nausea and/or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days with Photophobia and Phonophobia</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days with photophobia and phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Migraine Headaches with Prodromal Symptoms</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly migraine headaches with prodromal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Days on Which Acute Migraine Treatments are Taken per Month</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of days on which acute migraine treatments are taken per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression-Improvement (PGI-I) Rating</measure>
    <time_frame>3 Months</time_frame>
    <description>PGI-I rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Monthly Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline in the number of monthly headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Quality of Life Inventory (PedsQL) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from Baseline on the PedsQL total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Pediatric Migraine Disability Assessment test (PedMIDAS) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline on the PedMIDAS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Patient Satisfaction with Medication Questionnaire-Modified (PSMQ-M)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Change from baseline on the PSMQ-M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the C-SSRS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>PK: Serum concentration of galcanezumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Plasma concentration of CGRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Percentage of participants developing anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Initiate Migraine Prevention Medication</measure>
    <time_frame>16 Months</time_frame>
    <description>Proportion of participants who initiate migraine prevention medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">645</enrollment>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab PK Lead-In</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered by subcutaneous (SQ) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered by SQ injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by SQ injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_label>Galcanezumab PK Lead-In</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of migraine as defined by the International Headache Society
             International Classification of Headache Disorders (IHS ICHD-3) beta guidelines (1.1
             or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 6 months prior
             to screening.

        Exclusion Criteria:

          -  Participants who are taking, or are expected to take, therapeutic antibodies during
             the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).
             Prior use of therapeutic antibodies, other than antibodies to calcitonin gene-related
             peptide (CGRP) or its receptor, is allowed if that use was more than 12 months prior
             to baseline.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab or its excipients.

          -  Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor
             antibody, including those who have previously completed or withdrawn from this study
             or any other study investigating a CGRP antibody.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine and migraine with brainstem aura
             (previously basilar-type migraine) as defined by IHS ICHD-3 beta.

          -  History of any type of headache except for migraine, tension type headache, or
             medication overuse headache, as defined by IHS ICHD-3 beta, in the 3 months prior to
             randomization. For example, a history of post-traumatic headache in this 3-month
             period would not be allowed.

          -  History of traumatic head injury, associated with significant change in the quality or
             frequency of their headaches, including new onset of migraine following traumatic head
             injury.

          -  Participants with a known history of intracranial tumors or developmental
             malformations including Chiari malformations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>21st Century Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joshua Tobin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Little</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dinesh Talwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-521-2830</phone>
    </contact>
    <investigator>
      <last_name>Dane M. Shipp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcy Yonker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-281-5757</phone>
    </contact>
    <investigator>
      <last_name>Nandita M Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-644-1165</phone>
    </contact>
    <investigator>
      <last_name>Eva Maria Heurich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-654-2724</phone>
    </contact>
    <investigator>
      <last_name>Kelly Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Inst of Florida-Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-425-5100</phone>
    </contact>
    <investigator>
      <last_name>Linda S Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Akiva Daum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>321-331-6768</phone>
    </contact>
    <investigator>
      <last_name>Kavita Kalidas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-845-0500</phone>
    </contact>
    <investigator>
      <last_name>Paul K Winner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>678-705-7341</phone>
    </contact>
    <investigator>
      <last_name>Frank Berenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research LLC</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark A Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-593-8553</phone>
    </contact>
    <investigator>
      <last_name>Hossam AbdelSalam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-202-6322</phone>
    </contact>
    <investigator>
      <last_name>Arkadiy Stolyar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corp</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Egilius Spierings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-333-2200</phone>
    </contact>
    <investigator>
      <last_name>Gary D. Berman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Mercy Pediatric Clinical Research Unit</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jennifer Dilts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donald Johns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ashok Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226-0000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7162502000</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Williams McVige</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-636-4222</phone>
    </contact>
    <investigator>
      <last_name>Marielle Kabbouche-Samaha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-590-1719</phone>
    </contact>
    <investigator>
      <last_name>Christina L Szperka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Catalina Cleves-Bayon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-650-6155</phone>
    </contact>
    <investigator>
      <last_name>Nathan L Bennett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David L. Fried</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-867-6906</phone>
    </contact>
    <investigator>
      <last_name>Eric Remster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-2114</phone>
    </contact>
    <investigator>
      <last_name>Heidi Blume</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(453) 868-5131</phone>
    </contact>
    <investigator>
      <last_name>Nanette Debes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Neurologie und Psychiatrie</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>492011700350</phone>
    </contact>
    <investigator>
      <last_name>Astrid Gendolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Samuel Sanchez PSC</name>
      <address>
        <city>Caguas</city>
        <zip>00727</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877463136</phone>
    </contact>
    <investigator>
      <last_name>Karen Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7878402580</phone>
    </contact>
    <investigator>
      <last_name>Odette Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Headache Center of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Franchesca Fiorito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34932746606</phone>
    </contact>
    <investigator>
      <last_name>Patricia Pozo Rosich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz-NEURO</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34917277444</phone>
    </contact>
    <investigator>
      <last_name>Manuel Lara Lara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34961973910</phone>
    </contact>
    <investigator>
      <last_name>JOSE MIGUEL LAINEZ ANDRES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34983420000 87289</phone>
    </contact>
    <investigator>
      <last_name>Angel Luis Guerrero Peral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/migraine/CGAS#?postal=</url>
    <description>A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine</description>
  </link>
  <verification_date>March 1, 2020</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

